Industrial Biotechnology...Industrial Biotechnology 6th Year Competence in Life Sciences. Since 1999. An initiative of Go in gPublic 3 Special March 2013 Magazin GoingPublic Pflichtblatt

Industrial Biotechnology

Printed + E-Magazin + Web

Digital version: expanded to include multi-media content and functions – ideal for reading on the go!

6th Year

Industrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologySpecialSpecial

Vol. 6 (2015)Vol. 6 (2015)V

Biorefineries – Next Generation Biofuels – Biomass – Building Blocks –

Sustainability – Biobased Products – Plastics – Cosmetics – Biophar

ceu ticals – New Value Chains – International Alliances – Succes Stories

Life SciencesSerie

February 2015 – 12,50 EUR (D) – www.goingpublic.de/lifesciences1


Technologie - Finanzierung - Investment

Special

Vol. 6 (2015)

Biorefi neries – Next Generation Biofuels – Biomass – Building Blocks –

Sustainability – Biobased Products – Plastics – Cosmetics – Biophar ma-


Industrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyIndustrial BiotechnologyWho is who 2014?2014?2014?Auf über 120 Seiten: ca. 1.300 Adressen Adressen Adressen und Profile!

72 Investmentbanken

Industrial Biotechnology78

Industrial BiotechnologyIndustrial Biotechnology78

Industrial BiotechnologyIndustrial BiotechnologyFör

Industrial BiotechnologyIndustrial BiotechnologyFör

Industrial BiotechnologyIndustrial Biotechnologyderbanke

Industrial BiotechnologyIndustrial Biotechnologyderbanke

Industrial BiotechnologyIndustrial Biotechnologyn


Industrial BiotechnologyCorporate-Finance-Berater

Industrial BiotechnologyCorporate-Finance-Berater


Industrial BiotechnologyIndustrial BiotechnologyHR

Industrial BiotechnologyIndustrial BiotechnologyConsultants

Industrial BiotechnologyIndustrial Biotechnology(NEU!

Industrial BiotechnologyIndustrial Biotechnology)

Industrial BiotechnologyIndustrial Biotechnology(NEU!

Industrial Biotechnology)

Industrial Biotechnology(NEU!


Industrial BiotechnologyIndustrial BiotechnologyKapitalmarktversicher

Industrial Biotechnologyer

Industrial Biotechnologyer

Industrial Biotechnology(NEU!)(NEU!)

Industrial Biotechnology102Industrial BiotechnologyFinanzkommunikation: Industrial BiotechnologyFinanzkommunikation: Industrial BiotechnologyAIndustrial BiotechnologyAIndustrial BiotechnologygentuIndustrial BiotechnologygentuIndustrial BiotechnologyreIndustrial BiotechnologyreIndustrial Biotechnologyn Industrial Biotechnologyn Industrial Biotechnologyund Industrial Biotechnologyund Industrial BiotechnologyBIndustrial BiotechnologyBIndustrial Biotechnologyerater Industrial Biotechnologyerater Industrial Biotechnology(Industrial Biotechnology(Industrial BiotechnologyS. Industrial BiotechnologyS. Industrial Biotechnology(S. (Industrial Biotechnology(Industrial BiotechnologyS. Industrial Biotechnology(Industrial Biotechnology102)Industrial Biotechnology102)Industrial BiotechnologyHV-OrHV-OrHV ganisation (S. (S. ( 112)

Sonstige HV-Dienstleister HV-Dienstleister HV (S. (S. ( 118)

Nachrichtendienstleister (S. (S. ( 120)

Ratingagenturen (S. 121)

(unabhängige) Researchhäuser (S. 122)122)

124 Private-Equity-GesellschaftenPrivate-Equity-GesellschaftenPrivate-Equity-Gesellschaften:VC-/PE-Gesellschaften VC-/PE-Gesellschaften VC-/PE-Gesellschaften VC-/PE-Gesellschaften VC-/PE-Gesellschaften VC-/PE-Gesellschaften VC-/PE-Gesellschaften VC-/PE-Gesellschaften VC-/PE-Gesellschaften (S. (S. (S. 124)124)124)

Investoren en in Krisensituationen Krisensituationen (S. (S. ( 152)

InkubatorInkubatoren (S. 154)

156156 Private-Equity-DachfondsPrivate-Equity-DachfondsPrivate-Equity-DachfondsPrivate-Equity-DachfondsPrivate-Equity-DachfondsPrivate-Equity-DachfondsPrivate-Equity-Dachfonds159 Business-AngelsBusiness-AngelsBusiness-Angels-

NetzwerkeNetzwerke162 Rechtsanwalts-/SteuerRechtsanwalts-/SteuerRechtsanwalts-/Steuer-

beratungs-/Wberatungs-/Wberatungs-/Wirt schafts-t schafts-t prüfungssozietätenprüfungssozietätenprüfungssozietäten

184 WeitereiterWeiterW e Dienstleister:Dienstleister:Börsen mit mit Zulassungsbedingungen Zulassungsbedingungen (S. (S. ( 184)

Verbände/Institutionen/Behörerbände/Institutionen/Behörerbände/Institutionen/BehörVerbände/Institutionen/BehörV den (S. 190)

Seminar- - und KongrKongressveranstalter (S. (S. ( 192)

Sonstige Dienstleister Dienstleister (S. (S. ( 192)

neries – Next Generation Biofuels – Biomass – Building Blocks –


alue Chains – International Alliances – Succes Stories
















Life SciencesSerie

February 2015 – 12,50 EUR (D) – www.goingpublic.de/lifesciences1


Technologie - Finanzierung - Investment

Special

Vol. 6 (2015)

Biorefi neries – Next Generation Biofuels – Biomass – Building Blocks –



Date of publication 21st February 2015

Advertising close 9th February 2015

Special

In English language due to the international nature of the topic!

Provisional title page, subject to modification

Industrial Biotechnology 6th Year

Competence in Life Sciences. Since 1999.

An initiative of

6th Year

Goi

ngPu

blic

3 Special March 2013 www.goingpublic.de

MagazinGoingPublic

Pflichtblatt an allen deutschen Wertpapierbörsen

Industrial Biotechnology Industrial BiotechnologySPECIALSPECIAL

Markets – Technologies – Financing – Investments

Vol. 4Vol. 4

powered by

Das Kapitalmarktmagazin

2014

2013

2011

2012

Date of publication: 21st February 2015

Number of pages: approx. 64

Number of copies printed: approx. 6,000 (guaranteed)

Target group/readers: Sector experts from the chemical industry and specia-lists from related industries (such as cosmetics, texti-les, paper or environmental protection); decision ma-kers from the biotechnology sector as well as industry suppliers, service providers and consulting fi rms; inves-tors (institutional and private, venture capital compa-nies, business angels), entrepreneurs, start-ups, listed and established non-listed companies, the life sciences community (bio-regions, business plan competitions, research institutions, legal professionals), fi nancial ser-vices industry, politicians, scientists, associations and further multipliers.

E-magazine: Additional distribution as free E-magazine, promo-tion and distribution by partnering associations and networks; E-magazine included in the monthly newsletter ”LifeSciencesUpdate”, E-magazine to be published on www.goingpublic.de/lifesciences.

Distribution: The distribution goes beyond the monthly recipients of GoingPublic Magazin and the subscribers of Ventu-reCapital Magazin by the help of collaborations with multipliers such as associations and networks (e.g. VBU, BIO Germany, DECHEMA, GBM, VBIO, GDCh, VCW, ADT (German Federal Association of Innovation, Technology and Founder Centres), DIB, leading ven-ture capital companies which focus on life sciences and their portfolio companies, founders and participants in business plan competitions, listed and established non-listed companies. To optimise the distribution of the edition Industrial Biotechnology collaborations will also be sought with trade fairs, meetings and con-ferences which focus on industrial biotechnology, the bio-economy and fi nancing (examples: Life Science Forum, 8th International Conference on Bio-based Materials, World Congress on Industrial Biotechno logy, Achema, Bio International Convention, Biotechnica or the European Forum for Industrial Biotechnology and the Bio-based Economy).

VentureCapitalMagazin

Background and GoalsThe Life Sciences Series was launched in 2014. Its first edition in 2015 will, for the sixth time, focus on indus-trial biotechnology and the bio-economy. It is published in English and will appear in February 2015.

The bio-economy is becom-ing visible: in the European transport sector in 2013, 4.7% of the energy consu-med came from renewable sources, with a goal of 10% by 2020. Bioplastics are also taking off: the Institute for Bioplastics and Biocompo-sites expects to see global capacity increase five-fold to over 6,000 tonnes by 2017. The ”Halbzeitkonfe-renz Bioökonomie” demonstrated that ”Biobased” is already part of our everyday lives; bicycles, lubricants and wedding gowns are now being made from renewable raw materials.

The EU is positioning itself for the post-oil era. Scandinavia‘s wood and paper industry is a major source of raw materials, Belgium and the Nether-lands have the most bio-refineries and pilot faci-lities; Macedonia is planning to build a large cellu-lose bio-refinery with DuPont and Ethanol-Europe – Investors should start paying attention now. The purchase of Butalco by the global market leader in yeast production Lesaffre shows that early exits are possible. Those who fail to take part will miss out on the likely boom.

MarketBioplastics are not confined to soda bottles, packaging or wall dowels. FourMotors, with Ger-man singer Smudo at the wheel of the bio-racing

car, are taking pole position. DSM and Daimler are making chassis components from castor beans, Reverdia is offering bio-succinic acid for sustainable resins and coatings, Evonik is producing bio- polyamide, and Evolva biotech vanillin.

POET-DSM, Abengoa and DuPont are building cellu-lose refineries for in excess of USD 700 million with an annual capacity of 80 billion gallons in America‘s corn belt. The technology is flowing to the raw materials.

Capital and Stock ExchangePrivate Investments remain a bottleneck factor in Europe. The raising of USD 40 million of equity capital by agro-biotechs SGB and Fulcrum Bioenergy contrasts with the EUR 8.1million round of financing by enzyme specialists Direvo in Europe. France and other countries are sup-porting R&D with tax relief. Under Horizon 2020, ”Synergistic Funding” is financing projects with a range of funding pots.

Success StoriesBulk consumers are starting pilot projects and establishing value-added networks. Lufthansa is testing Amyris‘ bio-kerosene farnesene. Clariant is successfully testing its second generation fuel in Mercedes vehicles. BASF is also producing bio-succinic acid in a joint venture with Corbion Purac.

Biofuel-pioneer Smudo shows, what‘s driving tomorrow. Photo: FOUR MOTORS GmbH

Photo: Thinkstock/iStock/endopack

Key Topics By-product power sourcesWaste streams of lignocellulosic biomass are a new resource. But are energy-crop monocultures sustainable? What happens to whey, fl ue gas, pulp residues and other waste products? Europe already uses ¾ of its biomass, where do competitions arise? Which recyclable materials can be isolated directly, where is fermentation the only option? Is Bio-Naphta the cost-effective drop-in solution?

Factories of the FutureUntil now, research and development has primari-ly taken place in Europe and the United States, yet, considerable biomass is available in countries like Brazil, Indonesia and Russia. Are new industries developing in these countries? What cooperative relationships, business relationships and logistics networks are being developed? Which biotechnolo-gy strategies are countries like Norway, Canada and Malaysia pursuing? Will mega-clusters such as BIG-C connect them?

FinancingAccording to the European Investment Bank (EIB) there aren‘t any fi nancial bottlenecks in Europe. If

this is true, where are the multi-million investments hiding? Will the low-interest rates contribute to ad-ded private investments? Where is the round tab-le for the bio-economy, bringing banks, companies and policy-makers together? Is shale-gas deterring investors? Which classes of molecules are being forced out, which are being fostered? Will the focus on molecule specialities remain solely on cosmetics and food?

Further TopicsSuccess stories, technical papers, interviews with experts, market overviews and statistics in ”Indus-trial Biotechnology all refl ect the current times. Focusing on technology, fi nancing and investment, this edition reports on the latest trends in indust-rial biotechnology in the customary, in-depth way. Stock-exchange listed as well as small and medium sized businesses and investment forecasts all stand together on an equal footing to kick-start a wide-ranging debate on the further development of the biotech sector. At the same time a forum for colla-borations is created with profi les.

The Life Science SeriesLife Sciences, have been a signifi cant sector and technological focus of GoingPublic Magazin for around 16 years. Apart from cover stories, focus areas and transaction reporting (rounds of fi nancing, stock market launches, mergers, acquisitions etc.), up to fi ve specials appear annually. The GoingPublic Life Sciences Series was launched in 2014. Four issues will be published in 2015: “Industrial Biotech-nology“ (No. 1, 1/2015, 21.2., engl., approx. 64 p., 6th year), “Personalized Medicine“ (No. 2/2015, 18.4. approx. ca. 48 S., 5th year), “Biotechnology“ (No. 3/2015, 12.9., approx. 190 p., 17th year) and “Health“ (No. 4/2015, 31.10., approx. 64 p., 9th year.).

LifeSciencesUpdate supplements the offer since March 2013 as a monthly digital newsletter with editorial highlights, news, event tips, previews, reviews, cross links and more. The website www.goingpublic.de/lifesciences shows the range of editorial contributions on the internet. Here you can fi nd advance reports from the magazines, but also company reports about rounds of fi nancing, investment trends, mergers and acquisitions (M&A) and (patent) law topics, studies and events. The mission: cross media connection (magazine – web – event) of life sciences with knowledge and net-works relating to company fi nancing and the capital market.

Contact PartnerPartnerships/Advertising/ Karin Hofelich, Publishing Director Life Sciences, Munich Offi ce,Magazine Sales [email protected], Tel.: +49 (0) 89 – 2000 339-54, +49 (0) 177 – 4225 289

Editorial Office: Konstantin Riffl er, Konstantin Riffl er, Editor GoingPublic Magazin, riffl [email protected], Frankfurt Offi ce, Tel. +49 (0) 69 – 27 29 38 02

Concept consulting, BCNP Consultants GmbH, Dr. Holger Bengs, Anne Hachmann, Support & Editing: [email protected], Tel. +49 (0) 69 – 509 293 30, Internet: www.bcnp.com

GoingPublic Media AG l Hofmannstr. 7a l 81379 Munich l Germany l Tel.: +49(0)89 2000 339-54Contact Partner: Karin Hofelich ([email protected])

www.goingpublic.de/mediadaten

D. The ‚profile‘ advertisement (for large companies and small and medium sized businesses), economic deve-lopment agencies/clusters as well as investors

1/2 page portrait for only EUR 950 excluding VAT and including graphic design/layout

The layout of the half-page profi le is in three columns. In the left-hand column each company introduces themselves briefl y with a maximum of 800 characters (incl. spaces). The presen-tation includes a photograph of the building, the laboratory or the technology. The centre column contains information relating to the standard categories, areas of activity, ownership structure and fi nancing, partner, products/services, unique selling points and memberships. A maximum of 160 characters including spaces are available for each individual pie-ce of information. If one particular category is not used, additional characters will then be available for the remaining categories. The logo, contact data as well as a photograph of the team/CEO or similar will complete the profi le.

Attention: the fi nal deadline for the receipt of the information to be printed in the profi le is the 2nd February!

company name

short description (~800 characters)

field of activity~160 characters

ownership structure and financing~160 characters

partners~160 characters

technology~160 characters

products/services~160 characters

unique selling point~160 characters

membership in networks/associations~160 characters

addressstreetplz / city

telephone/telefaxxxx / xxx

e-mailxxx

web addressxxx

date of incorporation/number of employeesxxx / x

other~100 characters

company photo

company logo

photo ofCEO/team

Dr. Holger Bengs Anne HachmannKarin Hofelich Konstantin Riffler

Special„Industrial Biotechnology 2015“+++ 6th Year +++

Date of Publication: 21st Februar 2015Deadline for advertisements: 9th Februar 2015Delivery date for print: 13th Februar 2015

Fax reply form:+49 (0) 89-2000 339-39

send by email to: [email protected]

Yes, we would like to join!

Format

Colour

Please send us the complete media information or submit an offer for

Price information:

Advertising formats Euro scale 2C/3C/4C & b/w

2/1 page 5,200 EUR

1/1 page 2,900 EUR

1/2 page 1,900 EUR

1/3 page 1,600 EUR

Special advertising “company profile” (1/2 page) 950 EUR (incl. Layout)

Other formats On request!All prices plus VAT

We order _____ copies of the “Industrial Biotechnology” Special for a subscription price of 9.80 EUR instead of 12,50 EUR(incl. 7% VAT, excl. 1,80 EUR for mailing)!

Company data or stamp

Company Name, Surname

Street Zip Code, City

E-mail Telephone

Date/Signature

GoingPublic Media AG l Hofmannstr. 7a l 81379 Munich l Germany l Tel.: +49(0)89 2000 339-54Contact person: Karin Hofelich ([email protected])

www.goingpublic.de/mediadaten

Documents

Industrial Biotechnology...Industrial Biotechnology 6th Year Competence in Life Sciences. Since 1999. An initiative of Go in gPublic 3 Special March 2013 Magazin GoingPublic Pflichtblatt